KMT2A and leukemia: These data suggest that the inhibition of PLK-1 results in convincing anti-leukemic effects by the reduction in viability, induction of cell cycle arrest, and, finally, apoptosis in infant MLL fusion protein-driven leukemia with significantly less impact on both adult MLLr leukemia and control cells.